Global Atopic Dermatitis Treatment
Market Report
2024
Atopic Dermatitis Treatment Market Report 2024 (Global Edition)
Global Atopic Dermatitis Treatment Market size was USD 16.12 Billion in 2022. Atopic Dermatitis Treatment Industry's Compound Annual Growth Rate will be 15.60% from 2023 to 2030.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
|
Rating: 4.8 | Review: 7
Share your contact details to receive free updated sample copy/pages of the recently published edition of Atopic Dermatitis Treatment Market Report 2024.
Global Atopic Dermatitis Treatment Market Report 2024 Market Size Split by Drug Class (PDE-4 Inhibitor, Corticosteroids, Others, Biologics, Calcineurin Inhibitors), by Mode of Administration (Topical,...
Global Atopic Dermatitis Treatment Market size was USD 16.12 Billion in 2022. Atopic Dermatitis Treatment Industry's Compound Annual Growth Rate will be 15.60% from 2023 to 2030.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Atopic Dermatitis Treatment Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 15.6% |
| Market Split by Drug Class |
|
| Market Split by Mode of Administration |
|
| Market Split by Distribution Channel |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Atopic Dermatitis Treatment industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Atopic Dermatitis Treatment Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Atopic Dermatitis Treatment Market Report Description
Introduction of Atopic Dermatitis Treatment
Having a chronic condition called atopic dermatitis causes by red, itchy, swollen, and cracked skin. Treatment is necessary due to the possibility of white fluid leaking from the affected area. Typically starting in childhood, atopic dermatitis can worsen as one grows older. Several factors can cause atopic dermatitis, such as genetic abnormalities, environmental exposure, immune system dysfunction, and issues with skin permeability. Atopic dermatitis is more common overall, and as a result, the market for this condition is projected to experience significant growth thanks to ongoing advancements in drug development. The market is expected to expand due to the increasing demand for new biological and approved products, further driving the growth of the atopic dermatitis market.
These developments empower businesses to offer better-tailored solutions and services, which, in turn, contribute to the growth of the atopic dermatitis industry.
LEO Pharma A/S, a leading company in the field of medical dermatology on a global scale, launched AD Days around the World, an international initiative aimed at increasing awareness about atopic dermatitis (AD), which is the most common form of eczema. This campaign focuses on sharing the personal stories of individuals who are living with this condition.
What are the key driving factors of Atopic Dermatitis Treatment Market?
- Increasing Awareness of Atopic Dermatitis to Provide Viable Market Output
The market for AD people using herbal medicine, natural ointment, and ultraviolet therapy is boosted by increased awareness. Also, medical institutions provide education on AD and its primary home treatment. Furthermore, extensive research is being conducted to find fast relief for the disease. All of these factors are driving the market forward. For example, World Atopic Eczema Day was established in to raise awareness of AD internationally among Europeans. The initiative was created by the European Federation of Allergy and Airway Patients' Associations (EFA) and the International Federation of Dermatology Patients' Associations (Skin International).
The FDA has approved Dupixent (dupilumab) for children between 6 months and 5 years who have moderate-to-severe atopic dermatitis that is not effectively managed with prescribed topical treatments or when those treatments are not recommended.
The growth of the global atopic dermatitis market is propelled by the introduction of biologics & small molecules, premium-priced drugs that are replacing generic first-line and second-line therapeutics, and improved diagnostics. The market's growth rate is expected to be accelerated by the increasing prevalence of skin allergies and chronic disorders. The severity of atopic dermatitis varies from patient to patient, and the treatment procedures are tailored to the severity level. The rising healthcare expenditure and the growing popularity of these treatment procedures through digital advertisements are accelerating the global atopic dermatitis market growth.
(Source:www.sanofi.com/en/media-room/press-releases/2022/2022-06-07-20-45-00-2458243)
Factors Impacting on Atopic Dermatitis Market
-
Lack of Skilled Healthcare Professionals to Hinder Market Growth
In underdeveloped regions, there is a shortage of qualified healthcare professionals. This scarcity is mainly due to a lack of adequate training programs. As a result, healthcare facilities frequently require additional skilled doctors to meet the required level of care. One potential solution is for the government to offer various incentives to healthcare workers in public-sector hospitals and health centers. Some developed countries have tackled a similar problem by implementing reimbursement systems based on capitation and a pay-for-performance model. These approaches help balance the need to expand services and budget constraints.
Impact of COVID-19 on Atopic Dermatitis Treatment
The COVID-19 outbreak has caused more people to wash their hands frequently, resulting in dry and cracked skin that is more prone to infections in individuals with atopic dermatitis. Hand eczema has also increased due to repeated exposure to harsh soaps and hand sanitizers that strip the skin of natural oils. The pandemic has significantly impacted market growth during the peak stages of the COVID-19 crisis. However, with the easing of strict regulations on patient consultations at healthcare centers, the market is expected to experience growth in the forecast period.
We have various report editions of Atopic Dermatitis Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Atopic Dermatitis Treatment Market Insights Video
Competitive Landscape of Atopic Dermatitis Treatment Market
Market conditions for atopic dermatitis are quite competitive. There is a wide selection of atopic dermatitis service providers there, from major international corporations to specialized little enterprises. Globalization and technological development have increased rivalry among businesses to provide cutting-edge treatments for atopic dermatitis.
Atopic Dermatitis Treatment Industry News
April 2021: AbbVie, a company that specializes in biopharmaceuticals and focuses on conducting research and developing new drugs, has announced that the U.S. Food and Drug Administration (FDA) has chosen to extend the assessment period for the supplemental New Drug Application (sNDA) of upadacitinib. This medication shows promise as a potential treatment for adults and adolescents suffering from moderate to severe atopic dermatitis.
March 2020: The FDA has approved Pfizer Inc.'s supplemental New Drug Application (sNDA) for EUCRISA (crisaborole) ointment, 2%, lowering the minimum age requirement for patients with mild-to-moderate atopic dermatitis (AD), also known as eczema, from 24 months to 3 months.
Top Companies Market Share in Atopic Dermatitis Treatment Industry: (In no particular order of Rank)
- Asana Biosciences
- Arcutis Biotherapeutics
- Pfizer Inc.
- Dermavant
- Sanofi SA
- Astellas Pharma Inc
- Eli Lilly
- AbbVie Inc
- Regeneron Pharmaceuticals Inc
- Otsuka Holdings Co. Ltd
- Bayer AG
- Leo Pharma
- Galderma
- Novartis International AG
- Incyte
- Bristol-Myers Squibb
- Viatris
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
North America Atopic Dermatitis Treatment Market held a significant portion in 2022!
According to Cognitive Market Research, The North American market for atopic dermatitis held a significant portion of the global market in 2022 . The driving factors behind this growth are introducing new products, early treatment adoption, and lifestyle changes. Recent studies have shown that 40% of Americans are affected by moderate to severe atopic dermatitis, leading to emotional distress and physical discomfort, pain, and sleep disturbances for around 16.8 million individuals in the United States. This condition manifests as itchy rashes and patches primarily around the neck, face, and eyes. Furthermore, 18% of Canadians also suffer from atopic dermatitis, a visible skin disease that negatively impacts their quality of life by causing depression, anxiety, and psychosocial problems. Health Canada has approved CIBINQO (abrocitinib) as a treatment option for atopic dermatitis patients aged 12 years and older. However, many Canadian individuals with atopic dermatitis seek peer support and require mental health resources.
The Asia Pacific atopic dermatitis market is expected to experience the highest global compound annual growth rate (CAGR) of 15.7% during the aforementioned forecast period. India is expected to record the highest CAGR during the period. The expansion in this area can be attributed to the unmet needs of patients, increased medical expenses and the availability of adequate medical care. The Indian Dermatology Expert Board Members have issued numerous guidelines for managing atopic dermatitis in India. The country offers advanced drugs and treatments for various skin diseases, including atopic dermatitis. Many hospitals in India have started adopting treatments for this condition as the number of affected individuals continues to rise, largely due to climate change. In China, the incidence of atopic dermatitis has rapidly increased over the past decade, particularly among individuals between the ages of 10 and 30 who require treatment for this condition.
The current report Scope analyzes Atopic Dermatitis Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Atopic Dermatitis Treatment Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Atopic Dermatitis Treatment Market Analysis
Global Atopic Dermatitis Treatment Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Atopic Dermatitis Treatment Industry growth. Atopic Dermatitis Treatment market has been segmented with the help of its Drug Class, Mode of Administration Distribution Channel, and others. Atopic Dermatitis Treatment market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
By Drug Class, Atopic Dermatitis Treatment Market Segment Analysis:
According to Cognitive Market Research, Biologics possess a notable clinical edge in comparison to conventional topical treatments as they specifically address the root inflammatory mechanisms of the ailment, rather than solely addressing the symptoms. These drugs have a high specificity level, giving them a competitive edge. Biologics are primarily prescribed for severe cases, usually as a second or third-line treatment, for patients who have not responded to previous systemic therapies. Growth in the biologic segment is driven by increased demand due to their high potential, increasing number of approved products and a strong line of biologics for atopic dermatitis. Nemolizumab is currently administered by GALDERMA LABORATORIES, L.P. It is a monoclonal antibody under investigation. For its potential use in the treatment of pruritus and atopic dermatitis.
The PDE4 market is projected to experience substantial growth during the forecast timeframe as a result of the wide range of products available. One such product is Eucrisa (crisaborole ointment, 2%), which is a recommended PDE4 inhibitor.
- PDE-4 Inhibitor
- Corticosteroids
- Others
- Biologics
- Calcineurin Inhibitors
Atopic Dermatitis Treatment Market Share (%) by Drug Class in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Atopic Dermatitis Treatment Industry. Request a Free Sample PDF!
By Mode of Administration, the Topical segment is predicted to dominate the Atopic Dermatitis Treatment Market!
The topical segment is predicted to dominate the global market for atopic dermatitis. It is projected to experience significant growth with a high compound annual growth rate (CAGR) of 14.7% during the forecast period. Topic treatments are offered in various forms, such as creams, ointments, lotions, and gels, and are known for effectively reducing inflammation, itching, and skin dryness. The increasing inclination of healthcare providers to prescribe topical medications for patients with atopic dermatitis is a key factor driving the growth of this segment.
According to Cognitive Market Research, The oral segment of the global atopic dermatitis market is forecasted to display a consistent compound annual growth rate (CAGR) in the foreseeable future. The expected progression of the oral segment indicates an increase in the usage of oral pills by healthcare providers to manage symptoms when the skin disease has advanced. Furthermore, at-home therapies often incorporate oral medication for moderate to severe atopic dermatitis cases.
- Topical
- Injectable
- Oral
Atopic Dermatitis Treatment Market Share (%) by Mode of Administration in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Atopic Dermatitis Treatment Distribution Channel Segment Analysis
According to Cognitive Market Research, the global market was dominated by retail pharmacies in 2022, and it is projected to experience a substantial growth rate of 14.7% throughout the forecast period. Patients favor retail pharmacies due to their convenience and accessibility, a key driver of the segment's growth.
The hospital pharmacies segment held a substantial portion of the global atopic dermatitis market during the projected timeframe due to the increasing influx of patients to hospitals and their preference for obtaining medications from hospital pharmacies. Furthermore, the perception that hospital pharmacies are a reliable source for purchasing prescribed medications contributes to the growth of this segment.
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Author's Detail
David FullerSenior Analyst at Cognitive Market Research
I am working as a Senior Analyst with Cognitive Market Research in the areas of Industry Survey and Market Research/Analytics. I collaborate with CXOs, VPs, and other senior executives to understand their data needs and provide solutions and business strategy building.
Bio :
I am working as a Senior Analyst with Cognitive Market Research in the areas of Industry Survey and Market Research/Analytics. I collaborate with CXOs, VPs, and other senior executives to understand their data needs and provide solutions and business strategy building. I fulfill data requirements with thorough research and analytics. ME and My research team provide intelligence on industry stats, market structure, company profiles/Competition Analysis, Forecast Mapping, and Recently started providing the COVID-19 Impact Analysis.
Specialties: Industry research, Company analysis, Location Strategy, Tech Research, Change Management, Process Improvement, Peer Group Benchmarking, Startup Ecosystem, Crypto Research, COVID19 Impact Analysis, etc.
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Atopic Dermatitis Treatment Market is witnessing significant growth in the near future.
In 2023, the PDE-4 Inhibitor segment accounted for noticeable share of global Atopic Dermatitis Treatment Market and is projected to experience significant growth in the near future.
The Topical segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Asana Biosciences , Pfizer Inc. and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Frequently Asked Questions (FAQs)
The global market size for the atopic dermatitis market in 2022 was 16.12 USD billion.
The global market is expected to grow with a CAGR of 15.60% during the forecast period.
North America had the largest global atopic dermatitis market revenue share in 2022.
Asia Pacific will witness the fastest growth in the global atopic dermatitis market over the coming years.
United States had the largest global atopic dermatitis market revenue share in 2022.
The main drivers of the growth of the atopic dermatitis market are the rapid development of novel pipeline medications, the increasing demand for new biologics and product approvals, the favorable reimbursement practices in emerging nations, and the high prevalence of atopic dermatitis.
The biologics segment had the largest share in the global market by drug class.
In 2022, the retail pharmacies segment had a major revenue share in the global market in terms of distribution channels.
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Atopic Dermatitis Treatment Market
Latest Articles about Atopic Dermatitis Treatment Market
Having a chronic condition called atopic dermatitis causes by red, itchy, swollen, and cracked skin. Treatment is necessary due to the possibility of white fluid leaking from the affected area. Typically starting in childhood, atopic dermatitis can worsen as one grows older.
Cognitive Market Research noticed that the demand for atopic dermatitis treatment in a variety of industries including hospitals and clinics specialty dermatology clinics and pharmacies is the primary driver of significant growth in the global Atopic Dermatitis Treatment market
Sources from Manufacturing & Construction Industry
-
https://www.epa.gov/regulatory-information-sector/construction-sector-naics-23
-
https://www.usace.army.mil/Missions/Civil-Works/Engineering-and-Construction/
-
https://www.abs.gov.au/statistics/industry/building-and-construction
-
https://business.gov.au/planning/industry-information/construction-industry
-
https://www.usitc.gov/research_and_analysis/tradeshifts/2021/footwear
Atopic Dermatitis Treatment Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Drug Class | PDE-4 Inhibitor, Corticosteroids, Others, Biologics, Calcineurin Inhibitors |
| Mode of Administration | Topical, Injectable, Oral |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| List of Competitors | Asana Biosciences, Arcutis Biotherapeutics, Pfizer Inc., Dermavant, Sanofi SA, Astellas Pharma Inc, Eli Lilly, AbbVie Inc, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co. Ltd, Bayer AG, Leo Pharma, Galderma, Novartis International AG, Incyte, Bristol-Myers Squibb, Viatris |
Expand All
This chapter will help you gain GLOBAL Market Analysis of Atopic Dermatitis Treatment. Further deep in this chapter, you will be able to review Global Atopic Dermatitis Treatment Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Atopic Dermatitis Treatment Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Atopic Dermatitis Treatment Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Atopic Dermatitis Treatment Revenue Market Size By Region
-
-
1.3 Global Atopic Dermatitis Treatment Market Size By Drug Class 2019 -2031
-
1.3.1 PDE-4 Inhibitor Market Size
-
1.3.2 Corticosteroids Market Size
-
1.3.3 Others Market Size
-
1.3.4 Biologics Market Size
-
1.3.5 Calcineurin Inhibitors Market Size
-
-
1.4 Global Atopic Dermatitis Treatment Market Size By Mode of Administration 2019 -2031
-
1.4.1 Topical Market Size
-
1.4.2 Injectable Market Size
-
1.4.3 Oral Market Size
-
-
1.5 Global Atopic Dermatitis Treatment Market Size By Distribution Channel 2019 -2031
-
1.5.1 Hospital Pharmacies Market Size
-
1.5.2 Retail Pharmacies Market Size
-
1.5.3 Online Pharmacies Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Drug Class
-
1.7.3 Global Market Revenue Split By Mode of Administration
-
1.7.4 Global Market Revenue Split By Distribution Channel
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Atopic Dermatitis Treatment Market Size 2019 - 2031
-
2.1.1 North America Atopic Dermatitis Treatment Market Size By Country 2019 - 2031
-
2.1.2 North America Atopic Dermatitis Treatment Market Size by Drug Class 2019 -2031
-
2.1.2.1 North America PDE-4 Inhibitor Market Size
-
2.1.2.2 North America Corticosteroids Market Size
-
2.1.2.3 North America Others Market Size
-
2.1.2.4 North America Biologics Market Size
-
2.1.2.5 North America Calcineurin Inhibitors Market Size
-
-
2.1.3 North America Atopic Dermatitis Treatment Market Size by Mode of Administration 2019 -2031
-
2.1.3.1 North America Topical Market Size
-
2.1.3.2 North America Injectable Market Size
-
2.1.3.3 North America Oral Market Size
-
-
2.1.4 North America Atopic Dermatitis Treatment Market Size by Distribution Channel 2019 -2031
-
2.1.4.1 North America Hospital Pharmacies Market Size
-
2.1.4.2 North America Retail Pharmacies Market Size
-
2.1.4.3 North America Online Pharmacies Market Size
-
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Atopic Dermatitis Treatment Market Size 2019 - 2031
-
3.1.1 Europe Atopic Dermatitis Treatment Market Size By Country 2019 - 2031
-
3.1.2 Europe Atopic Dermatitis Treatment Market Size by Drug Class 2019 -2031
-
3.1.2.1 Europe PDE-4 Inhibitor Market Size
-
3.1.2.2 Europe Corticosteroids Market Size
-
3.1.2.3 Europe Others Market Size
-
3.1.2.4 Europe Biologics Market Size
-
3.1.2.5 Europe Calcineurin Inhibitors Market Size
-
-
3.1.3 Europe Atopic Dermatitis Treatment Market Size by Mode of Administration 2019 -2031
-
3.1.3.1 Europe Topical Market Size
-
3.1.3.2 Europe Injectable Market Size
-
3.1.3.3 Europe Oral Market Size
-
-
3.1.4 Europe Atopic Dermatitis Treatment Market Size by Distribution Channel 2019 -2031
-
3.1.4.1 Europe Hospital Pharmacies Market Size
-
3.1.4.2 Europe Retail Pharmacies Market Size
-
3.1.4.3 Europe Online Pharmacies Market Size
-
-
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Atopic Dermatitis Treatment Market Size 2019 - 2031
-
4.1.1 Asia Pacific Atopic Dermatitis Treatment Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Atopic Dermatitis Treatment Market Size by Drug Class 2019 -2031
-
4.1.2.1 Asia Pacific PDE-4 Inhibitor Market Size
-
4.1.2.2 Asia Pacific Corticosteroids Market Size
-
4.1.2.3 Asia Pacific Others Market Size
-
4.1.2.4 Asia Pacific Biologics Market Size
-
4.1.2.5 Asia Pacific Calcineurin Inhibitors Market Size
-
-
4.1.3 Asia Pacific Atopic Dermatitis Treatment Market Size by Mode of Administration 2019 -2031
-
4.1.3.1 Asia Pacific Topical Market Size
-
4.1.3.2 Asia Pacific Injectable Market Size
-
4.1.3.3 Asia Pacific Oral Market Size
-
-
4.1.4 Asia Pacific Atopic Dermatitis Treatment Market Size by Distribution Channel 2019 -2031
-
4.1.4.1 Asia Pacific Hospital Pharmacies Market Size
-
4.1.4.2 Asia Pacific Retail Pharmacies Market Size
-
4.1.4.3 Asia Pacific Online Pharmacies Market Size
-
-
Chapter 5 South America Market Analysis
-
5.1 South America Atopic Dermatitis Treatment Market Size 2019 - 2031
-
5.1.1 South America Atopic Dermatitis Treatment Market Size By Country 2019 - 2031
-
5.1.2 South America Atopic Dermatitis Treatment Market Size by Drug Class 2019 -2031
-
5.1.2.1 South America PDE-4 Inhibitor Market Size
-
5.1.2.2 South America Corticosteroids Market Size
-
5.1.2.3 South America Others Market Size
-
5.1.2.4 South America Biologics Market Size
-
5.1.2.5 South America Calcineurin Inhibitors Market Size
-
-
5.1.3 South America Atopic Dermatitis Treatment Market Size by Mode of Administration 2019 -2031
-
5.1.3.1 South America Topical Market Size
-
5.1.3.2 South America Injectable Market Size
-
5.1.3.3 South America Oral Market Size
-
-
5.1.4 South America Atopic Dermatitis Treatment Market Size by Distribution Channel 2019 -2031
-
5.1.4.1 South America Hospital Pharmacies Market Size
-
5.1.4.2 South America Retail Pharmacies Market Size
-
5.1.4.3 South America Online Pharmacies Market Size
-
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Atopic Dermatitis Treatment Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Atopic Dermatitis Treatment Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Atopic Dermatitis Treatment Market Size by Drug Class 2019 -2031
-
6.1.2.1 Middle East and Africa PDE-4 Inhibitor Market Size
-
6.1.2.2 Middle East and Africa Corticosteroids Market Size
-
6.1.2.3 Middle East and Africa Others Market Size
-
6.1.2.4 Middle East and Africa Biologics Market Size
-
6.1.2.5 Middle East and Africa Calcineurin Inhibitors Market Size
-
-
6.1.3 Middle East and Africa Atopic Dermatitis Treatment Market Size by Mode of Administration 2019 -2031
-
6.1.3.1 Middle East and Africa Topical Market Size
-
6.1.3.2 Middle East and Africa Injectable Market Size
-
6.1.3.3 Middle East and Africa Oral Market Size
-
-
6.1.4 Middle East and Africa Atopic Dermatitis Treatment Market Size by Distribution Channel 2019 -2031
-
6.1.4.1 Middle East and Africa Hospital Pharmacies Market Size
-
6.1.4.2 Middle East and Africa Retail Pharmacies Market Size
-
6.1.4.3 Middle East and Africa Online Pharmacies Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Atopic Dermatitis Treatment Market Size by Drug Class 2019 -2031
-
7.1.2 Country 1Atopic Dermatitis Treatment Market Size by Mode of Administration 2019 -2031
-
7.1.3 Country 1Atopic Dermatitis Treatment Market Size by Distribution Channel 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Atopic Dermatitis Treatment Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Asana Biosciences
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Arcutis Biotherapeutics
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Pfizer Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Dermavant
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Sanofi SA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Astellas Pharma Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Eli Lilly
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 AbbVie Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Regeneron Pharmaceuticals Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Otsuka Holdings Co. Ltd
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Bayer AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Leo Pharma
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Galderma
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Novartis International AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 Incyte
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
8.2.16 Bristol-Myers Squibb
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.16.2 Business Overview
-
8.2.16.3 Financials (Subject to data availability)
-
8.2.16.4 Product Types Specification
-
8.2.16.5 Business Strategy
-
8.2.16.6 S.W.O.TAnalysis
-
-
8.2.17 Viatris
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.17.2 Business Overview
-
8.2.17.3 Financials (Subject to data availability)
-
8.2.17.4 Product Types Specification
-
8.2.17.5 Business Strategy
-
8.2.17.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Drug Class Analysis 2019 -2031, will provide market size split by Drug Class. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Drug Class Analysis 2019 -2031
-
10.1 PDE-4 Inhibitor
-
10.1.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by PDE-4 Inhibitor 2019 -2031
-
-
10.2 Corticosteroids
-
10.2.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Corticosteroids 2019 -2031
-
-
10.3 Others
-
10.3.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Others 2019 -2031
-
-
10.4 Biologics
-
10.4.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Biologics 2019 -2031
-
-
10.5 Calcineurin Inhibitors
-
10.5.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Calcineurin Inhibitors 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Mode of Administration Analysis 2019 -2031
-
11.1 Topical
-
11.1.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Topical 2019 - 2031
-
-
11.2 Injectable
-
11.2.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Injectable 2019 - 2031
-
-
11.3 Oral
-
11.3.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Oral 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Distribution Channel Analysis 2019 -2031
-
12.1 Hospital Pharmacies
-
12.1.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Hospital Pharmacies 2019 -2031
-
-
12.2 Retail Pharmacies
-
12.2.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Retail Pharmacies 2019 -2031
-
-
12.3 Online Pharmacies
-
12.3.1 Global Atopic Dermatitis Treatment Revenue Market Size and Share by Online Pharmacies 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Atopic Dermatitis Treatment market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Research Methodology Implemented by David Fuller and Team
- 1.1 Atopic Dermatitis Treatment Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Atopic Dermatitis Treatment Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Atopic Dermatitis Treatment Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Atopic Dermatitis Treatment Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Atopic Dermatitis Treatment Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Atopic Dermatitis Treatment Market
Key Questions Answered By Atopic Dermatitis Treatment Market Report 2024
| Why PDE-4 Inhibitor have a significant impact on Atopic Dermatitis Treatment market? |
| What are the key factors affecting the PDE-4 Inhibitor and Corticosteroids of Atopic Dermatitis Treatment Market? |
| What is the CAGR/Growth Rate of Topical during the forecast period? |
| By type, which segment accounted for largest share of the global Atopic Dermatitis Treatment Market? |
| Which region is expected to dominate the global Atopic Dermatitis Treatment Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
